EUVIMEDEUVIMED entdecken
Open Access

Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival

Anatilde Gonzalez Guerrico, David Hillman, Jeffery Karnes, Brian Davis, Steven Gaston, George Klee

Journal of Circulating Biomarkers · 2017

DOI: 10.1177/1849454417720151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Circulating Biomarkers, 2017. Verfasst von Anatilde Gonzalez Guerrico und 5 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Rochester, MN, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Free human kallikrein 2 (free-hK2) and hK2 pro-form (pro-hK2) have been found to be increased in tumor tissues and serum from patients with prostate cancer. We established semiautomatic assays for free-hK2 and pro-hK2 using a research version of the Beckman Coulter ACCESS2 system. Serum samples from a cohort of 189 men undergoing radical prostatectomy for known high-risk disease were assayed for Prostate-Specific Antigen (PSA), free-PSA, free-hK2, and pro-hK2. Univariate Cox regression and multivariate models were used to predict both Gleason scores and progression-free survival (PFS). Free-hk2 levels ≥80 ng/L were predictive of both Gleason scores ≥7 (p = 0.04) and PFS (p = 0.03). PSA ≥8.0 µg/L also was predictive of PFS (p = 0.02). However, neither % free-PSA nor pro-hK2, when treated as continuous or cutoff variables were associated with Gleason score or PFS. Multivariable models showed that clinical stage T1c versus T2/T3, Gleason score ≥7, and PSA ≥8.0 µg/L or clinical stage T1c versus T2/T3, Gleason scores ≥7, and free-hK2 ≥80 ng/L were among the best models predicting PFS. Both free-hK2 and PSA in conjunction with clinical stage and Gleason score are good predictors of PFS in prostate cancer.

Schlagwörter

Stichwörter der Autor:innen

Free-hK2PSApro-hK2progression-free survivalprostate cancer

Autor:innen und Institutionen

  • Mayo Clinic, Rochester, MN, USA.
  • Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
  • Department of Urology, Mayo Clinic, Rochester, MN, USA.
  • Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
  • Beckman Coulter, Chaska, MN, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Guerrico, A. G., Hillman, D., Karnes, J., Davis, B., Gaston, S., & Klee, G. (2017). Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival. Journal of Circulating Biomarkers. https://doi.org/10.1177/1849454417720151

Vancouver

Guerrico AG, Hillman D, Karnes J, Davis B, Gaston S, Klee G. Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival. Journal of Circulating Biomarkers. 2017. doi:10.1177/1849454417720151

BibTeX
@article{Guerrico2017,
  author = {Guerrico, Anatilde Gonzalez and Hillman, David and Karnes, Jeffery and Davis, Brian and Gaston, Steven and Klee, George},
  title = {Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival},
  journal = {Journal of Circulating Biomarkers},
  year = {2017},
  doi = {10.1177/1849454417720151}
}
Kostenlos starten →